aetiolog
epidemiolog
common
cold
possibl
prevent
common
cold
syndrom
caus
discuss
feasibl
prophylaxi
consid
blackwel
scientif
public
symptom
common
cold
due
brief
episod
infecti
rhiniti
major
case
one
wide
varieti
ofvirus
implic
causal
organ
unfortun
technic
difficulti
isol
virus
greatli
reduc
frequenc
virolog
diagnosi
either
attempt
achiev
clinic
nasopharyng
nasal
congest
rhinorrhea
promin
sore
throat
cough
transient
malais
common
headach
low
grade
pyrexia
occasion
occur
acut
symptom
usual
last
day
condit
usual
clear
within
day
commonest
caus
syndrom
infect
one
mani
rhinovirus
coronavirus
varieti
common
respiratori
virus
includ
parainfluenza
respiratori
syncyti
influenza
adenovirus
may
caus
clinic
indistinguish
syndrom
virus
infect
replic
epitheli
cell
princip
line
nasal
caviti
destroy
mani
cell
process
cell
regener
function
recoveri
occur
recoveri
rise
titr
antibodi
specif
direct
infect
viru
often
shown
patient
serum
symptom
infecti
common
cold
need
distinguish
episod
allerg
perenni
rhiniti
perhap
rhiniti
due
chemic
irrit
howev
distinct
usual
made
care
historytak
bear
mind
distinct
pathogenesi
viral
rhiniti
compar
syndrom
clinic
virolog
chang
occur
common
cold
studi
detail
cours
experiment
infect
volunt
given
intranas
inocul
rhinovirus
coronavirus
respons
follow
done
year
sever
centr
notabl
common
cold
unit
salisburi
england
initi
experiment
infect
gave
much
help
identif
virus
respons
recent
infect
volunt
prove
particularli
use
assess
effect
antivir
drug
respiratori
volunt
best
studi
condit
isol
prevent
experiment
viral
present
address
divis
microbiolog
reagent
qualiti
control
central
public
health
laboratori
colindal
avenu
london
inocul
affect
intercurr
minor
respiratori
infect
clinic
virolog
observ
made
daili
result
express
quantit
clinic
score
system
measur
titr
viru
recover
nasal
wash
collect
day
succeed
inocul
figur
show
observ
made
group
volunt
receiv
inocul
rhinoviru
type
sign
symptom
score
includ
relev
upper
respiratori
infect
although
emphasi
place
object
effect
amount
nasal
discharg
subject
report
symptom
minor
nasal
obstruct
sore
throat
incub
period
rhinoviru
infect
two
day
subject
ill
rapidli
reach
peak
declin
succeed
day
concurr
symptom
common
cold
viru
multipli
nasal
epitheli
cell
discharg
nasal
secret
cycl
viral
replic
one
infect
epitheli
cell
probabl
take
h
complet
cycl
thousand
infecti
virion
releas
cell
disintegr
turn
infect
fresh
cell
thp
second
third
day
viru
inocul
process
reach
peak
figur
concentr
viru
undilut
secret
may
sometim
much
infecti
unit
per
ml
viru
titr
usual
declin
rapidli
succeed
mean
titr
rhinoviru
nasal
wash
day
mani
subject
rhinoviru
excret
ceas
within
day
although
other
may
continu
day
perhap
occasion
longer
minor
infect
often
subclin
ie
viru
shed
occur
absenc
symptom
numer
studi
volunt
other
indic
viru
shed
transient
state
symptomless
subject
carri
shed
rhinoviru
long
period
identifi
infect
cell
damag
viru
multipli
within
shed
ciliat
epithelium
figur
human
ciliat
epitheli
cell
variou
stage
degener
demonstr
sometim
larg
number
nasal
secret
collect
height
cold
multipl
viru
nose
induc
antibodi
respons
appropri
viral
antigen
virusspecif
antibodi
serum
shown
rise
natur
experiment
cold
suitabl
virolog
techniqu
usual
viru
neutral
use
detect
moder
level
antibodi
indic
immun
homolog
viru
unfortun
number
serolog
distinct
virus
great
impli
gener
immun
cold
difficult
gener
durat
immun
specif
viru
type
vari
individu
type
viru
also
number
time
subject
immun
boost
natur
reexposur
viru
antibodi
iga
class
secretori
antibodi
respiratori
virus
includ
rhinovirus
also
demonstr
nasal
secret
probabl
also
play
role
imrnun
j
h
e
virus
caus
cold
virus
respons
cold
list
tabl
assess
rel
common
causal
agent
common
cold
syndrom
difficulti
ascrib
exact
percentag
frequenc
group
reflect
technic
difficulti
isol
mani
rhinovirus
human
respiratori
coronavirus
seri
cold
studi
caus
remain
undefin
b
subtyp
c
type
one
type
type
half
caus
respintori
tract
infect
categor
state
new
group
ofcaus
virus
remain
discov
proport
ofcold
caus
small
virus
list
tabl
said
associ
typic
clinic
effect
rhinovirus
coronavirus
common
cold
syndrom
howev
influenza
virus
respiratori
syncyti
virus
other
known
caus
seriou
infect
also
less
typic
produc
cold
clinic
indistinguish
due
rhinovirus
coronavirus
member
picornaviru
group
thu
biolog
relat
poliovirus
enterovirus
footandmouth
diseas
viru
cattl
nm
diamet
consist
nucleoprotein
rnacontain
core
surround
capsid
built
protein
subunit
antigen
specif
type
incorpor
although
mani
type
ofrhinoviru
grown
readili
tissu
cultur
vitro
clear
tropism
respiratori
epitheli
cell
particularli
nose
facil
replic
nose
may
relat
optim
growth
temperatur
rather
optim
method
cultur
identif
well
recogn
human
embryon
fibroblast
gener
use
although
certain
sublin
heiaa
cell
also
suitabl
isol
rhinovirus
patient
attempt
nasal
swab
provid
better
specimen
purpos
throat
swab
nasal
wash
collect
instil
balanc
salt
solut
nose
still
better
specimen
usual
inocul
similar
cell
cultur
incub
roller
apparatu
growth
rhinoviru
indic
develop
typic
cytopath
effect
test
usual
done
confirm
labil
virus
treatment
ph
lower
rhinoviru
type
vari
greatli
eas
grown
cell
cultur
mani
failur
due
use
unsuit
cultur
condit
insuffici
sensit
cell
line
certain
strain
rhinoviru
adapt
growth
tissu
cultur
preliminari
growth
organ
cultur
prepar
human
embryo
nasal
e
p
h
e
l
im
although
embryon
tissu
need
prepar
cultur
may
difficult
obtain
differenti
epitheli
cell
cultur
provid
sensit
growth
rhinovirus
coronavirus
nasal
polyp
use
purpos
may
less
satisfactori
epithelium
less
healthi
identif
serotyp
rhinoviru
difficult
number
type
larg
type
techniqu
establish
use
antisera
type
signific
proport
isol
prove
untyp
l
z
groupreact
serolog
test
rhinovirus
avail
mean
retrospect
diagnosi
rhinoviru
infect
easili
establish
use
pair
sera
collect
acut
convalesc
stage
ill
case
mani
viral
infect
howev
serotyp
caus
infect
known
antibodi
respons
measur
neutral
test
tissu
cultur
human
respiratori
coronavirus
first
describ
year
still
poorli
understood
technic
difficulti
isol
clinic
specimen
although
natur
condit
infect
host
cell
rhinovirus
ie
nasal
epitheli
cell
otherwis
biolog
similar
rhinovirus
rnacontain
virus
nm
diamet
nucleoprotein
core
enclos
proteinand
lipidcontain
membran
surround
halo
corona
clubshap
project
spike
consist
glycoprotein
two
earli
isol
name
former
strain
relat
type
grown
tissu
cultur
wherea
type
relat
often
grown
organ
cultur
human
embryon
nasal
epithelium
natur
limit
studi
done
exampl
number
serotyp
subtyp
exist
yet
establish
coronavirus
caus
typic
cold
studi
volunt
establish
mean
incub
period
slightli
longer
rhinoviru
cold
day
compar
day
coryza
particularli
profus
usual
natur
condit
diagnosi
coronaviru
infect
often
establish
technic
difficulti
involv
reason
preval
infect
probabl
often
underestim
full
assess
import
await
simpl
effect
virolog
test
h
e
serolog
test
current
avail
includ
complement
fixat
neutral
test
complement
fixat
haemagglutinationinhibit
recent
singl
radial
haemolysi
test
elisa
test
infect
also
recent
describ
cold
occur
year
round
temper
climat
common
winter
summer
longterm
virolog
studi
minor
respiratori
infect
carri
variou
popul
group
epidemiolog
rhinoviru
infect
coronaviru
infect
review
studi
indic
children
young
adult
particularli
suscept
rhinoviru
infect
virus
preval
autumn
perhap
spring
women
may
experi
infect
men
perhap
closer
contact
young
children
exchang
virus
freeli
frequent
infect
sever
differ
viru
serotyp
may
circul
commun
inde
famili
one
time
preval
serotyp
vari
year
year
consist
evid
certain
type
overal
common
other
inde
indic
gradual
shift
preval
serotyp
period
find
epitom
difficulti
success
vaccin
rhinovirus
epidemiolog
behaviour
coronavirus
differ
rhinovirus
coronaviru
infect
seem
preval
midwint
earli
spring
decembermarch
serolog
studi
use
antigen
prepar
avail
viru
type
suggest
infect
zzgerel
virus
preval
everi
year
possibl
restrict
number
viru
type
continu
recircul
presum
immun
gener
transient
also
evid
recircul
virus
may
antigen
subtyp
partli
immun
present
knowledg
antigen
structur
human
respiratori
coronavirus
immun
inadequ
allow
confid
predict
feasibl
vaccin
earli
studi
show
cold
like
spread
via
infect
droplet
expel
respiratori
tract
recent
shown
manual
transmiss
also
compar
import
two
rout
spread
yet
final
evalu
adult
possess
antibodi
singl
rhinoviru
serotyp
thu
immun
immun
induc
previou
infect
often
account
failur
cold
spread
contact
howev
recent
experiment
studi
rate
transmiss
two
rhinovirus
close
contact
antibodyfre
recogn
cold
may
associ
episod
acut
bronchiti
particularli
subject
whose
lower
respiratori
tract
alreadi
damag
relaps
asthma
bronchiti
predispos
children
wheezi
bronchiti
associ
cold
sinus
otiti
media
also
clear
recogn
mucos
damag
swell
hypersecret
disrupt
ciliari
clearanc
mechan
predispos
bacteri
infect
readili
reveal
bacteriolog
investig
howev
compar
difficulti
carri
similar
virolog
investig
mean
role
virus
bronchiti
infect
asthma
sinus
otiti
media
often
ignor
forgotten
nevertheless
role
virus
particularli
rhinovirus
initi
attack
bronchiti
well
document
rel
high
titr
rhinovirus
cultur
p
u
tm
correspond
virolog
studi
acut
sinus
otiti
media
seldom
report
spector
et
al
describ
adenoviru
infect
sinus
asthmat
patient
evan
et
detail
microbiolog
studi
patient
clinic
evid
sinus
recov
rhinoviru
acut
case
author
also
note
aspir
obtain
sinu
punctur
acut
case
show
less
leucocyt
per
aspir
gener
yield
bacteria
anoth
studi
hamori
et
recov
virus
rhinovirus
influenza
viru
parainfluenza
virus
sinus
examin
bear
mind
technic
difficulti
isol
respiratori
virus
alreadi
refer
may
reason
assum
true
rate
involv
virus
probabl
time
suggest
avail
figur
would
thu
repres
signific
proport
case
acut
sinus
may
well
relev
failur
antibiot
therapi
sometim
report
although
failur
achiev
adequ
antibiot
concentr
site
infect
also
clearli
import
role
viral
infect
otiti
media
fulli
investig
although
abil
respiratori
syncyti
viru
caus
middl
ear
infect
well
recent
associ
influenza
b
infect
otiti
media
appear
systemat
attempt
made
cultur
respiratori
virus
includ
rhinovirus
middl
ear
exud
inform
topic
clearli
need
h
e
control
common
respiratori
viral
infect
thc
possibl
use
vaccin
fulli
investig
vaccin
influenza
b
infect
common
use
reason
effect
littl
overal
effect
face
great
mass
respiratori
viral
infect
experiment
vaccin
parainfluenza
respiratori
syncyti
viru
use
children
studi
adenoviru
vaccin
limit
success
use
group
armi
recruit
howev
problem
vaccin
rhinovirus
remain
unsolv
experiment
vaccin
limit
success
although
case
rhinoviru
vaccin
restat
recent
littl
support
view
minor
immunolog
crossreact
demonstr
rhinoviru
serotyp
suliici
provid
basi
design
use
multival
vaccin
follow
suggest
rhinoviru
infect
may
possibl
spread
manual
rout
interest
interrupt
rout
mean
control
ordinari
thorough
hand
wash
soap
water
remov
viru
contamin
hand
health
educ
may
reason
promot
view
hand
wash
avoid
finger
nostril
conjunctiva
could
reduc
chanc
selfinocul
person
whose
finger
becom
contamin
secret
acut
infect
patient
h
e
possibl
use
connect
virucid
compound
hand
also
n
v
et
g
e
gener
attempt
prophylaxi
interrupt
viru
transmiss
take
account
evid
import
young
children
dissemin
infect
use
immunopotenti
compound
levamisol
prevent
upper
respiratori
infect
consid
valu
prove
forego
comment
antigen
divers
respiratori
virus
poor
prospect
success
vaccin
emphas
need
form
prophylaxi
therapi
antivir
chemotherapi
receiv
much
attent
field
notabl
treatment
herp
simplex
viru
infect
consider
advanc
divers
biolog
type
respiratori
virus
broadli
reactiv
antivir
compound
would
consider
practic
advantag
antivir
compound
howev
specif
particular
viru
group
activ
amantadin
exampl
restrict
influenza
virus
compound
rather
weakli
activ
consensu
recent
opinion
significantli
toxic
proven
valu
use
suitabl
epidem
u
n
yet
antirhinoviru
drug
clinic
use
although
mani
compound
inhibit
growth
rhinovirus
ziitro
studi
use
experiment
prophylact
trial
human
volunt
volunt
inocul
defin
respiratori
viru
provid
ideal
system
placebocontrol
doubl
blind
evalu
antivir
drug
work
recent
r
ei
e
w
e
compound
select
clinic
evalu
rhinoviru
infect
ideal
highli
effect
inhibitor
growth
wide
rang
rhinoviru
type
tissu
cultur
good
inhibitori
activ
organ
cultur
human
nasal
epithelium
addit
encourag
featur
adequ
anim
model
studi
human
rhinoviru
infect
provid
chimpanze
gibbon
first
investig
antirhinoviru
activ
compound
vivo
may
experi
done
man
potenti
new
drug
trial
must
cours
preced
full
toxicolog
investig
mani
antirhinoviru
compound
far
studi
poorli
solubl
pharmacolog
properti
favour
activ
nasal
epitheli
cell
vivo
experiment
trial
often
administ
nasal
spray
drop
highli
effici
nasal
mucociliari
clearanc
mechan
appear
enhanc
difficulti
maintain
adequ
concentr
compound
site
infect
far
specif
antirhinoviru
compound
shown
suffici
activ
man
merit
develop
variou
promis
compound
investig
alreadi
indic
wide
spectrum
antivir
prophylaxi
therapi
would
consider
theoret
advantag
compar
narrow
spectrum
synthet
compound
natur
antivir
substanc
interferon
induc
seem
close
theoret
ideal
possibl
use
respiratori
infect
rightli
receiv
consider
attent
synthet
natur
occur
interferon
induc
use
prophylact
control
trial
rhinoviru
infect
volunt
benefici
effect
unfortun
strike
risk
toxic
compound
limit
dosag
use
exogen
administr
human
interferon
also
investig
similar
placebocontrol
doubl
blind
experi
volunt
interferon
prepar
human
leucocyt
given
high
frequent
dosag
nasal
spray
success
prevent
experiment
infect
volunt
inocul
r
h
n
v
rs
scarciti
expens
human
interferon
recent
discoveri
benefici
role
neoplast
well
infecti
diseas
meant
effect
respiratori
tract
infect
yet
fulli
explor
product
interferon
newer
techniqu
includ
genet
engin
remedi
defici
experiment
studi
use
human
nasal
epithelium
confirm
prolong
contact
epitheli
cell
high
concentr
interferon
necessari
induct
antivir
state
experi
date
antivir
drug
interferon
give
reason
suppos
prophylaxi
even
therapi
viral
respiratori
infect
ultim
prove
feasibl
form
therapi
risk
treatment
need
compar
risk
disabl
inher
condit
itselfand
reason
seriou
disabl
viral
respiratori
infect
first
target
medic
whose
longterm
effect
necessarili
initi
unknown
form
antivir
therapi
found
suitabl
seriou
infect
need
prove
low
toxic
routin
use
common
cold
justifi
u
r
conclus
common
cold
caus
sever
differ
group
virus
rhinovirus
antigen
type
coronavirus
commonest
virus
replic
nasal
epitheli
cell
infecti
viru
shed
nasal
discharg
concurr
develop
symptom
variabl
degre
specif
immun
follow
infect
measur
suitabl
virolog
test
patient
serum
rhinovirus
usual
grown
tissu
cultur
laboratori
correct
cultur
condit
use
isol
strain
may
aid
use
organ
cultur
human
embryon
nasal
epithelium
nasal
organ
cultur
also
necessari
cultiv
mani
coronavirus
technic
difficulti
meant
full
evalu
pathogen
role
rhinovirus
coronavirus
slow
still
complet
rhinoviru
infect
may
spread
airborn
manual
rout
occur
year
round
especi
autumn
wherea
coronaviru
infect
common
midwint
earli
spring
rhinovirus
implic
play
role
bronchiti
wheezi
bronchiti
children
role
acut
sinus
otiti
media
adequ
investig
vaccin
cold
viral
complic
feasibl
great
multipl
antigen
type
prophylaxi
therapi
wide
spectrum
antivir
substanc
interferon
would
ideal
solut
doubleblind
placebo
control
studi
use
interferon
rhinovirusinfect
volunt
given
encourag
result
similar
experi
volunt
use
specif
antirhinoviru
compound
yet
reveal
drug
activ
enough
clinic
use
although
compound
good
inhibitori
activ
tissu
cultur
organ
cultur
studi
present
control
may
attempt
interrupt
rout
viral
transmiss
long
term
solut
may
lie
antivir
chemotherapi
